Xeris Biopharma Holdings, Inc. (XERS)
NASDAQ: XERS · Real-Time Price · USD
3.095
+0.035 (1.14%)
Nov 21, 2024, 11:43 AM EST - Market open
Xeris Biopharma Holdings Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for XERS stock have an average target of 4.87, with a low estimate of 3.00 and a high estimate of 6.60. The average target predicts an increase of 57.35% from the current stock price of 3.10.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for XERS stock from 3 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $6 → $6.6 | Strong Buy | Maintains | $6 → $6.6 | +113.25% | Nov 11, 2024 |
| Piper Sandler | Piper Sandler | Buy → Hold Downgrades $3 | Buy → Hold | Downgrades | $3 | -3.07% | Nov 11, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $6 | Strong Buy | Reiterates | $6 | +93.86% | Aug 15, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $6 | Strong Buy | Reiterates | $6 | +93.86% | May 31, 2024 |
| Piper Sandler | Piper Sandler | Buy Reiterates $4 → $3 | Buy | Reiterates | $4 → $3 | -3.07% | May 10, 2024 |
Financial Forecast
Revenue This Year
197.27M
from 163.91M
Increased by 20.35%
Revenue Next Year
229.11M
from 197.27M
Increased by 16.14%
EPS This Year
-0.41
from -0.45
EPS Next Year
-0.25
from -0.41
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 204.5M | 250.9M | 305.3M | ||
| Avg | 197.3M | 229.1M | 272.8M | ||
| Low | 187.6M | 196.1M | 240.0M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 24.8% | 27.2% | 33.3% | ||
| Avg | 20.3% | 16.1% | 19.1% | ||
| Low | 14.4% | -0.6% | 4.8% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.37 | -0.09 | 0.21 | ||
| Avg | -0.41 | -0.25 | 0.07 | ||
| Low | -0.42 | -0.39 | -0.05 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.